avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2013-0-4-30-40avk-205Research ArticleБОЛЕЗНИ СЕРДЦА И СОСУДОВВСЯ ПРАВДА О ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙВСЯ ПРАВДА О ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙВёрткинА. Л.ВёрткинА. Л.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

kafedrakf@mail.ruСкотниковА. С.СкотниковА. С.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

kafedrakf@mail.ruНосоваА. В.НосоваА. В.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

kafedrakf@mail.ruХовасоваН. О.ХовасоваН. О.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

kafedrakf@mail.ruАлгиянЕ. А.АлгиянЕ. А.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

kafedrakf@mail.ruГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова»РоссияГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова»Russian Federation201328082013043040Copyright © Вёрткин А.Л., Скотников А.С., Носова А.В., Ховасова Н.О., Алгиян Е.А., 20132013Вёрткин А.Л., Скотников А.С., Носова А.В., Ховасова Н.О., Алгиян Е.А.Вёрткин А.Л., Скотников А.С., Носова А.В., Ховасова Н.О., Алгиян Е.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/205

Проблема ведения пациентов с ФП является одной из наиболее актуальных в кардиологии и внутренней медицине в целом. Это обусловлено высоким риском смертности и развитием тяжёлых осложнений при ФП. В аспекте коморбидной отягощённости усложняется вопрос лекарственной терапии при ФП, в частности антитромботической. Однако новые лекарственные препараты, стремительно входящие в клиническую практику, становятся более эффективными, безопасными, доступными и удобными в применении. Наиболее актуальной является задача обеспечения адекватной медикаментозной профилактики развития тромботических осложнений. И, несомненно, центральным звеном в реализации этой задачи является амбулаторная служба медицинской помощи. К сожалению, реальное состояние ведения таких пациентов амбулаторно не соответствует современным рекомендациям и важности проблемы. Клинические наблюдения амбулаторных, стационарных пациентов и умерших больных с мерцательной аритмией, а также выполнение рекомендаций Российского и Европейского обществ кардиологов стали предметом данной статьи.

The management of the patients with atrial fibrillation is the global problem of the modern cardiology and internal medicine because of the associated high mortality risk and severe complications. Drug therapy, especially antithrombotic, becomes a difficult question in case of patient with comorbidity conditions. Though there are some new more effective and safe drugs that becomes more popular and convenient for patients. To reduce the amount of thrombotic complications is the main aspect. And only the outpatient departments can provide patients with atrial fibrillation with the adequate antithrombotic prevention. But nowadays this field doesn’t work as it should according to the European and National Guidelines. So this article speaks about alive and dead patients with atrial fibrillation, about their management in out-patient and in-patient department and about the way they should be treated according to Guidelines.

фибрилляция предсердийтромботические осложненияинсультострый инфаркт миокардатромбоэмболия лёгочной артериикоморбидностьамбулаторная службаривароксабанварфариндабигатрана этексилатантитромботическая терапияatrial fibrillationthrombotic complicationsischemic strokemyocardial infarctionpulmonary embolismcomorbidityout-patient carerivaroxabanwarfarindabigatran etexilateantithrombotic therapyкомпания «Байер»ReferencesAtrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials // Arch Intern Med. 1994. Vol. 154 (13). P. 1449-1457.Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials // Arch Intern Med. 1994. Vol. 154 (13). P. 1449-1457.Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. Vol. 33 (21). P. 2719-2747.Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. Vol. 33 (21). P. 2719-2747.Fang M.C., Go A.S., Chang Y., Borowsky L.H. et al. Warfarin discontinuation after starting warfarin for atrial fibrillation // Circ Cardiovasc Qual Outcomes. 2010. Vol. 3 (6). P. 624-631.Fang M.C., Go A.S., Chang Y., Borowsky L.H. et al. Warfarin discontinuation after starting warfarin for atrial fibrillation // Circ Cardiovasc Qual Outcomes. 2010. Vol. 3 (6). P. 624-631.Fox C.S., Parise H., D’Agostino R.B.Sr. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring // JAMA. 2004. Vol. 291. P. 2851–2855.Fox C.S., Parise H., D’Agostino R.B.Sr. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring // JAMA. 2004. Vol. 291. P. 2851–2855.Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J. 2010. Vol. 31. P. 967–975.Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J. 2010. Vol. 31. P. 967–975.Fuster V. et al. ACC/AHA/ESC guidelines for the management of patients with atrial brillation // J. Am. Coll. Cardiol. 2001. Vol. 38. P. 1231–1266. Nieuwlaat R. et al. The Euro Heart Survey on Atrial Fibrillation // Am. Heart J. 2007. Vol. 153. P. 1006–1012.Fuster V. et al. ACC/AHA/ESC guidelines for the management of patients with atrial brillation // J. Am. Coll. Cardiol. 2001. Vol. 38. P. 1231–1266. Nieuwlaat R. et al. The Euro Heart Survey on Atrial Fibrillation // Am. Heart J. 2007. Vol. 153. P. 1006–1012.Goldstein L.B., Akin D.R., Samsa G.P. et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices // Stroke. 1995. Vol. 26 (9). P. 1607-1615.Goldstein L.B., Akin D.R., Samsa G.P. et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices // Stroke. 1995. Vol. 26 (9). P. 1607-1615.Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.Hart R.G., Pearce L.A., McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators // Stroke. 1999. Vol. 30 (6). P. 1223-1229.Hart R.G., Pearce L.A., McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators // Stroke. 1999. Vol. 30 (6). P. 1223-1229.Heeringa J., Deirdre A.M. van der Kuip et al. // European Heart Journal. 2006. Vol. 27. Р. 949–953.Heeringa J., Deirdre A.M. van der Kuip et al. // European Heart Journal. 2006. Vol. 27. Р. 949–953.Hylek E.M., Go A.S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation // N. Engl. J. Med. 2003. Vol. 349 (11). P. 1019-1026.Hylek E.M., Go A.S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation // N. Engl. J. Med. 2003. Vol. 349 (11). P. 1019-1026.Kirchhof P., Auricchio A., Bax J. Outcome parameters for trials in atrial fibrillation: executive summary // Eur .Heart J. 2007. Vol. 28 (22). P. 2803-2817.Kirchhof P., Auricchio A., Bax J. Outcome parameters for trials in atrial fibrillation: executive summary // Eur .Heart J. 2007. Vol. 28 (22). P. 2803-2817.Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest. 2010. Vol. 137 (2). P. 263-272.Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest. 2010. Vol. 137 (2). P. 263-272.Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study // Circulation. 2004. Vol. 110 (9). P. 1042-1046.Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study // Circulation. 2004. Vol. 110 (9). P. 1042-1046.Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials // BMJ Open. 2012. Vol. 2. e001592.Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials // BMJ Open. 2012. Vol. 2. e001592.Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. 2005. Vol. 26. P. 2422–2434.Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. 2005. Vol. 26. P. 2422–2434.Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011 Vol. 365(10). P. 883-891.Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011 Vol. 365(10). P. 883-891.Pisters R., Lane D. A, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey // Chest. 2010. Vol. 138 (5). P. 1093-1100.Pisters R., Lane D. A, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey // Chest. 2010. Vol. 138 (5). P. 1093-1100.Stöllberger C., Schneider B., Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? // Chest. 2003. Vol. 124 (6). P. 2356-2362.Stöllberger C., Schneider B., Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? // Chest. 2003. Vol. 124 (6). P. 2356-2362.Sun Y., Hu D. The link between diabetes and atrial fibrillation: cause or correlation? // J. Cardiovasc. Dis. 2010. Vol. 1. P. 10-11.Sun Y., Hu D. The link between diabetes and atrial fibrillation: cause or correlation? // J. Cardiovasc. Dis. 2010. Vol. 1. P. 10-11.Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrilla-tion: a systematic review // Am. J. Med. 2006. Vol. 119 (448). e1–e19.Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrilla-tion: a systematic review // Am. J. Med. 2006. Vol. 119 (448). e1–e19.Tonje A. Aksnes and Sverre E. Kjeldsen. A link between hypertension and atrial fibrillation: methods of treatment and prevention // Current Vascular Pharmacology. 2010. Vol. 6. P. 769-774.Tonje A. Aksnes and Sverre E. Kjeldsen. A link between hypertension and atrial fibrillation: methods of treatment and prevention // Current Vascular Pharmacology. 2010. Vol. 6. P. 769-774.Vidaillet H., Granada J.F., Chyou P. et al. A population-based study of mortality among patients with atrial fibrillation or flutter // Am. J. Med. 2002. Vol. 113 (5). P. 365-370.Vidaillet H., Granada J.F., Chyou P. et al. A population-based study of mortality among patients with atrial fibrillation or flutter // Am. J. Med. 2002. Vol. 113 (5). P. 365-370.Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited // Lancet. 2009. Vol. 373. P. 155-166.Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited // Lancet. 2009. Vol. 373. P. 155-166.

The authors declare that there are no conflicts of interest present.